Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma: Is the addition of subcutaneous interferon-α-2b beneficial?

Hepatology Research

Volumn 39, Issue 3, 2009, Pages 223-230

  Takaki Hamabe, Satoe ^a   Yamasaki, Takahiro ^a   Saeki, Issei ^a   Harima, Yohei ^a   Okita, Kohsuke ^a   Terai, Shuji ^a   Sakaida, Isao ^a  

^a YAMAGUCHI UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Advanced hepatocellular carcinoma; Hepatic arterial infusion chemotherapy; Interferon (IFN) 2b; Prognostic factor

Indexed keywords

ALPHA FETOPROTEIN; ALPHA2B INTERFERON; ANTINEOPLASTIC AGENT; CISPLATIN; EPIRUBICIN; FLUOROURACIL; FOLINATE CALCIUM; FOLINATE CALCIUM PLUS FOLINIC ACID; FOLINIC ACID; IODINATED POPPYSEED OIL; MITOMYCIN C; ONDANSETRON; RECOMBINANT ALPHA2B INTERFERON; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CHEMOEMBOLIZATION; CLINICAL ARTICLE; DOSE RESPONSE; DRUG EFFICACY; FEMALE; HUMAN; LIVER CELL CARCINOMA; LOW DRUG DOSE; MALE; MICROWAVE THERAPY; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; PROGNOSIS; RADIOFREQUENCY ABLATION; SURVIVAL RATE; SURVIVAL TIME; VOMITING;

EID: 69249222983     PISSN: 13866346     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2008.00458.x     Document Type: Article

References (37)

1. Okuda K, Ohtsuki T, Obata H et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer 1985; 56: 918-28.
2. The Cancer of the Liver Italian Program (CLIP) investigators. A new prognostic system for patients with hepatocellular carcinoma: A retrospective study of 435 patients. Hepatology 1998; 28: 751-5.
3. Leung TW, Tang AM, Zee B et al. Factors predicting response and survival in 149 patients with unresectable hepatocellular carcinoma treated by combination cisplatin, interferon-alpha, doxorubicin and 5-fluorouracil chemotherapy. Cancer 2002; 94: 421-7.
4. Chung YH, Song BC, Lee GC et al. Combined therapy consisting of intraarterial cisplatin infusion and systemic interferon-α for hepatocellular carcinoma patients with major portal vein thrombosis or distant metastasis. Cancer 2000; 88: 1986-91.
5. Ando E, Yamashita F, Tanaka M et al. A novel chemotherapy for advanced hepatocellular carcinoma with tumor thrombosis of the main trunk of the portal vein. Cancer 1997; 79: 1890-6.
6. Okuda K, Tanaka M, Shibata J et al. Hepatic arterial infusion chemotherapy with continuous low dose administration of cisplatin and 5-fluorouracil for multiple recurrence of hepatocellular carcinoma after surgical treatment. Oncol Rep 1999; 6: 587-91.
7. Yamasaki T, Kurokawa F, Shirahashi H et al. Novel arterial infusion chemotherapy using cisplatin, 5-fluorouracil, and leucovorin for patients with advanced hepatocellular carcinoma. Hepatol Res 2002; 23: 7-17.
8. Yamasaki T, Kurokawa F, Takami T et al. Arterial infusion chemotherapy using cisplatin, 5-fluorouracil, and isovorin for patients with advanced hepatocellular carcinoma, pilot study: Is a high dose of the biochemical modulator effective? Hepatol Res 2003; 27: 36-44.
9. Yamasaki T, Kimura T, Kurokawa F et al. Prognostic factors in patients with advanced hepatocellular carcinoma receiving hepatic arterial infusion chemotherapy. J Gastroenterol 2005; 40: 70-8.
10. O'Connell MJ. A phase III trial of 5-fluorouracil and leucovorin in the treatment of advanced colorectal cancer. Cancer 1989; 63: 1026-30.
11. Poon MA, O'Connell MJ, Moertel CG et al. Biochemical modulation of fluorouracil: Evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. J Clin Oncol 1989; 7: 1407-17.
12. Buroker TR, O'Connell MJ, Wieand HS et al. Randomized comparison of two schedules of fluorouracil and leucovorin in the treatment of advanced colorectal cancer. J Clin Oncol 1994; 12: 12-20.
13. Urabe T, Kaneko S, Matsushita E, Unoura M, Kobayashi K. Clinical pilot study of intrahepatic arterial chemotherapy with methotrexate, 5-fluorouracil, cisplatin and subcutaneous interferon-alpha-2b for patients with locally advanced hepatocellular carcinoma. Oncology 1998; 55: 39-47.
14. Sakon M, Nagano H, Dono K et al. Combined intraarterial 5-fluorouracil and subcutaneous interferon-α therapy for advanced hepatocellular carcinoma with tumor thrombi in the major portal branches. Cancer 2002; 94: 435-42.
15. Ota H, Nagano H, Sakon M et al. Treatment of hepatocellular carcinoma with major portal vein thrombosis by combined therapy with subcutaneous interferon-α and intra-arterial 5-fluorouracil; role of type I interferon receptor expression. Br J Cancer 2005; 93: 557-64.
16. Obi S, Yoshida H, Toune R et al. Combination therapy of intraarterial 5-fluorouracil and systemic interferon-alpha for advanced hepatocellular carcinoma with portal venous invasion. Cancer 2006; 106: 1990-7.
17. Ebara M, Ohoto M, Sugiura N et al. Percutaneous ethanol injection for the treatment of small hepatocellular carcinoma. Study of 95 patients. J Gastroenterol Hepatol 1990; 5: 616-26.
18. Yamasaki T, Matsuzaki Y, Irie S et al. Percutaneous hot water injection therapy (PHoT) for treatment of hepatocellular carcinoma: A comparison with percutaneous ethanol injection therapy (PEIT). Int Hepatol Commun 1995; 3: 305-9.
19. Yamasaki T, Kurokawa F, Shirahashi H, Kusano N, Hironaka K, Okita K. Percutaneous radiofrequency ablation therapy with combined angiography and computed tomography assistance for patients with hepatocellular carcinoma. Cancer 2001; 91: 1342-8.
20. Matsui O, Kadoya M, Yoshikawa J et al. Small hepatocellular carcinoma: treatment with subsegmental transcatheter arterial embolization. Radiology 1993; 188: 79-83.
21. Sakurai M, Okamura J, Kuroda C. Transcatheter chemoembolization effective for treating hepatocellular carcinoma: A histopathologic study. Cancer 1984; 54: 387-92.
22. Liver Cancer Study Group of Japan. [The General Rules for the Clinical and Pathological Study of Primary Liver Cancer, 4th edn.] Tokyo: Kanehara, 2000. (In Japanese.)
23. Kudo M, Chung H, Osaki Y. Prognostic staging system for hepatocellular carcinoma (CLIP score): Its value and limitations, and a proposal for a new staging system, the Japan Integrated Staging Score (JIS score). J Gastroenterol 2003; 38: 207-15.
24. Oken MM, Creech RH, Tormey DC et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5: 49-55.
25. Seki T, Wakabayashi M, Nakagawa T et al. Ultrasonically guided percutaneous microwave coagulation therapy for small hepatocellular carcinoma. Cancer 1994; 74: 817-25.
26. Pugh RNH, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973; 60: 646-9.
27. Kaplan EL, Meier P. Nonparametric estimation from incomplete observation. J Am Stat Assoc 1958; 53: 457-81.
28. Llovet JM, Sala M, Castells L et al. Randomized controlled trial of interferon treatment for advanced hepatocellular carcinoma. Hepatology 2000; 31: 54-8.
29. Shwartz EL, Hoffman M, O'Connor CJ, Wadler S. Stimulation of 5-fluorouracil metabolic activation by interteron-alpha in human colon carcinoma cells. Biochem Biophys Res Commun 1992; 323: 425-8.
30. Eguchi H, Nagano H, Yamamoto H et al. Augmentation of antitumor activity of 5-fluorouracil by interferon α is associated with up-regulation of p27Kip1 in human hepatocellular carcinoma cells. Clin Cancer Res 2000; 6: 2881-90.
31. Kondo M, Nagano H, Wada H et al. Combination of IFN-α and 5-fluorouracil induces apoptosis through IFN-α/β receptor in human hepatocellular carcinoma cells. Clin Cancer Res 2005; 11: 1277-86.
32. Pestka S. The human interferon alpha species and receptors. Biopolymers 2000; 55: 254-87.
33. Yano H, Yanai Y, Momosaki S et al. Growth inhibitory effects of interferon-α subtypes vary according to human liver cancer cell lines. J Gastroenterol Hepatol 2006; 21: 1720-5.
34. Glue P, Fang JW, Rouzier-Panis R et al. Pegylated interferon-α 2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group. Clin Pharmacol Ther 2000; 68: 556-67.
35. Yano H, Ogasawara S, Momosaki S et al. Growth inhibitory effects of pegylated IFN α-2b on human liver cancer cells in vitro and in vivo. Liver Int 2006; 26: 964-75.
36. Yamasaki T, Saeki I, Okita K et al. Is an arterial infusion chemotherapy with pegylated interferon-alpha-2b effective for advanced hepatocellular carcinoma? J Gastroenterol Hepatol 2007; 22 (Suppl 2): A193.
37. Ando E, Tanaka M, Yamashita F et al. Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis: Analysis of 48 cases. Cancer 2002; 95: 277-87.